ACE and myocardial infarction: In patients reclassified as secondary myocardial infarction, just 45 and 58% were established on aspirin or a lipid-lowering therapy, 45% were on a beta-blocker, and 45% were on an angiotensin-converting enzyme inhibitor (Table 1).